Hydrafinil (aka 9-Fluorenol) is a novel eugeroic nootropic that is very similar in action to Modafinil. It was originally developed as a research compound by a biopharmaceutical company named Cephalon Pharmaceuticals to promote wakefulness and alertness. Results from the animal study reported a 39% increase in effectiveness at improving wakefulness over a 4 hour period when compared to Modafinil.¹ Due to its reported efficacy as a eugeroic agent, it is becoming popular among advanced nootropics users. Interestingly, users report less stimulating effects than Modafinil, but a greater ability to promote vigilance. Other reported benefits include attentional enhancement, increased motivation, subtle mood boost, improved cognitive function and ability to learn.

Compared to other popular eugeroic nootropics, Hydrafinil (Fluorenol) may have three main advantages: lower price, reduced stimulation and superior eugeroic efficacy.

Key benefits:

•   Increased alertness and wakefulness
•   Reduced fatigue and tiredness
•   Better concentration
•   Enhanced mental energy
•   Higher productivity

Recommended dosage:

The recommended daily dosage of Hydrafinil (Fluorenol) is 50 mg. As it is a powerful eugeroic nootropic you should not exceed the recommended daily dosage.

Mechanisms of action:

The precise mechanism of action is still unknown. However, a few possible mechanisms have been proposed. Firstly, it is believed that Hydrafinil (Fluorenol) may function as a weak dopamine reuptake inhibitor, which means that it increases the levels of dopamine neurotransmitter. As a result, a number of cognitive processes are improved. Secondly, it has been hypothesised that Hydrafinil (Fluorenol) acts as a serotonin 5-HT6 receptor antagonist. 5-HT6 receptors are located in the central nervous system (CNS) and it appears that their blockage can lead to improvements of cognitive performance in many different learning and memory paradigms.² In addition, serotonin and its system plays a very important role in both cognitive and behavioural control. Therefore, some of the mild mood improvements reported following the use of Hydrafinil (Fluorenol) are attributed to this system.

Chemical structure:

Side effects:

Based on the current available evidence, Hydrafinil (Fluorenol) is reported to be safe. However, most of this evidence is anecdotal. Therefore, more human studies/trials with scientific evidence and analysis of its long-term effects need to be done.

Compound facts:

Serving size: 1 tablet

Servings per bottle: 120

Amount per serving: Hydrafinil (Fluorenol) 50 mg

This product is free from: Artificial Flavours, Colours & Preservatives, Lactose, Yeast & Gluten

Suitable for: Vegetarians and Vegans

Warning:

Dietary products should not be used as a substitute for a well-balanced and healthy diet.
Store in a cool dry place, out of reach of children.
Do not use if you are pregnant or breastfeeding.

Disclaimer:

✝ These statements have not been evaluated by the Food and Drug Administration (FDA) The above products are not intended to diagnose, treat, cure or prevent any disease. You should consult a physician before taking a new product or a nootropic. This product should not be taken by pregnant or nursing mothers, people suffering from cardiovascular disease or those under 18 years of age.

Any studies cited here are not conclusive and are limited to their closed environment nature; they might not determine ones experience with a nootropic, due to a large number of unaccounted variables falling outside the scope of such studies.

The reviews available here are the opinions of contributors who may or may have not used these products, and do not necessarily represent the views of ThoughtFoods. These reviews represent one’s opinion and should not be taken as fact or recommendation. ThoughtFoods makes no warranty to the accuracy of information provided by these reviews.

Read legal disclaimer

References:

1. Dunn, D. et al. (2012). Wake promoting agents: search for next generation modafinil, lessons learned: part III, Bioorg Med Chem Lett. 22 (11), 3751-3.

2. Upton, N. et al. (2008). 5-HT6 receptor antagonists as novel cognitive enhancing agents for Alzheimer’s diseas, Neurotherapeutics. 5 (3), 458-69.

Reviews